Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Running, not enrolling

Conditions studied: Non-small Cell Lung Cancer (NSCLC)

In brief

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Key facts

Study ID

NCT07215962

Run by

Bristol-Myers Squibb

People needed

300

Starts

2024-11-22

Expected to finish

2026-03-01

Last updated by the study team

2025-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Have positive or unknown EGFR or ALK mutation before the index date
• Have a gap of > 120 days between metastatic NSCLC diagnosis and index date
• Were included in a clinical trial for 1L therapy
• Enter a hospice within 6 months of the follow-up will be excluded
• Have other concurrent primary cancer diagnoses

Where it is running

• Florida Cancer Specialists & Research Institute — Fleming Island, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.